Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $48,701 | $69,203 | $58,924 | $121,394 |
| - Cash | $11,628 | $3,094 | $11,247 | $14,548 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $37,073 | $66,109 | $47,676 | $106,846 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$8,103 | -$7,792 | -$11,732 | -$6,826 |
| % Margin | – | – | – | – |
| Net Income | -$8,485 | -$8,202 | -$11,732 | -$6,826 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.25 | -0.32 | -0.47 | -0.29 |
| % Growth | 21.9% | 31.9% | -62.1% | – |
| Operating Cash Flow | -$6,350 | -$8,091 | -$9,683 | -$5,437 |
| Capital Expenditures | -$0 | -$0 | $0 | $0 |
| Free Cash Flow | -$6,350 | -$8,091 | -$9,683 | -$5,437 |